Efficacy And Safety Of Anti-PD-1/PD-L1 Antibodies In Combination With Bevacizumab And Metronomic Cyclophosphamide In Patients With Non-Small Cell Lung Cancer And Cutaneous Melanoma Previously Treated With Immune Checkpoint Blockade

NCT07130032 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

90

Enrollment

NETWORK

Sponsor class

Conditions

Metastatic Non-small Cell Lung Cancer (NSCLC)
Metastatic Cutaneous Melanoma

Interventions

COMBINATION_PRODUCT: reICB regimen (NSCLC)
COMBINATION_PRODUCT: reICB regimen (melanoma)

Sponsor

EuroCityClinic LLC

Collaborators

[object Object]